Project 3 Control of Erythroid Differentiation by Transcription Elongation, Leonard I. Zon

NIH RePORTER · NIH · P01 · $433,420 · view on reporter.nih.gov ↗

Abstract

Abstract Hematopoiesis is regulated by transcription factors that activate lineage-specific programs. Transcription initiates, and pauses; the pause is then released, a process guided by cdk9, a kinase that phosphorylates Pol II. TIF1γ is a chromatin factor that is mutated in the bloodless moonshine zebrafish mutant: we have demonstrated that a mouse knockout of TIF1γ has decreased marrow erythropoiesis, no B cells, and expanded myelopoiesis. Using chemical genetics in the zebrafish, we found that clofibrate and leflunomide, activators of the nuclear receptors PPARα and SXR, rescue blood development in the moonshine mutant. We now propose to examine the genetic program that establishes this rescue, including an evaluation of gene expression in the rescued mutants. We will purify the PPARα and SXR complexes by affinity tagging and mass spectroscopy, and use zebrafish genetics to establish the downstream pathways that affect the rescue. A prior genetic screen for moonshine demonstrated rescue with mutations in the PAF1 complex or in spt5, both of which regulate transcription elongation. The paf1 zebrafish mutant is rescued by mating to a cdk9 mutant, which suggests that some transcripts hyper-elongate in the paf1 mutant. A recent large-scale knockdown screen for chromatin factors that are required for erythropoiesis during zebrafish development revealed that antisense morpholinos to 6 chromatin factors reduce red blood cell development, and knockdown of 9 chromatin factors increases erythropoiesis: we will assess whether these chromatin factor genes can be rescued by mutations in PAF1, spt5, or cdk9. We will also determine whether activators of specific nuclear hormone pathways can rescue the chromatin factor mutants. Our study will provide a comprehensive analysis of chromatin factors and how they regulate transcription elongation, and will offer the clinical opportunity to modify these pathways for the treatment of blood diseases such as sickle cell anemia and thalassemia. 1

Key facts

NIH application ID
10146451
Project number
5P01HL032262-39
Recipient
BOSTON CHILDREN'S HOSPITAL
Principal Investigator
LEONARD Ira ZON
Activity code
P01
Funding institute
NIH
Fiscal year
2021
Award amount
$433,420
Award type
5
Project period
1997-07-01 → 2022-03-31